{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:07:14Z","timestamp":1792487234261,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"DOI":"10.7759\/cureus.51894","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T02:19:54Z","timestamp":1704766794000},"source":"Crossref","is-referenced-by-count":4,"title":["Non-steroidal Anti-inflammatory Drug (NSAID)-, Potassium Supplement-, Bisphosphonate-, and Doxycycline-Mediated Peptic Ulcer Effects: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Camryn  L","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas  T","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raegan  B","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Behara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpadevi","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Paladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S0300-5089(21)00614-3","article-title":"Epidemiology of peptic ulcer disease","volume":"13","author":"Kurata JH","year":"1984","unstructured":"Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. Clin Gastroenterol. 1984, 13:289-307.","journal-title":"Clin Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000323958","article-title":"Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality","volume":"84","author":"Lau JY","year":"2011","unstructured":"Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011, 84:102-13. 10.1159\/000323958","journal-title":"Digestion"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.75.6.625","article-title":"The incidence of duodenal and gastric ulcers in a large health maintenance organization","volume":"75","author":"Kurata JH","year":"1985","unstructured":"Kurata JH, Honda GD, Frankl H. The incidence of duodenal and gastric ulcers in a large health maintenance organization. Am J Public Health. 1985, 75:625-9.","journal-title":"Am J Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"5","author":"Lanas A","year":"2017","unstructured":"Lanas A, Chan FK. Peptic ulcer disease. Lancet. 2017, 5:613-24. 10.1016\/S0140-6736(16)32404-7","journal-title":"Lancet"},{"key":"ref5","article-title":"Risk factors of perioperative mortality from complicated peptic ulcer disease in Africa: systematic review and meta-analysis","volume":"7","author":"Peiffer S","year":"20201","unstructured":"Peiffer S, Pelton M, Keeney L, et al.. Risk factors of perioperative mortality from complicated peptic ulcer disease in Africa: systematic review and meta-analysis. BMJ Open Gastroenterol. 20201, 7:e000350.","journal-title":"BMJ Open Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.12.009","article-title":"Diagnosis and treatment of peptic ulcer disease","volume":"132","author":"Kavitt RT","year":"2019","unstructured":"Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. Am J Med. 2019, 132:447-56. 10.1016\/j.amjmed.2018.12.009","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(16)30412-6","article-title":"Peptic ulcer pathophysiology","volume":"75","author":"Mertz HR","year":"19911","unstructured":"Mertz HR, Walsh JH. Peptic ulcer pathophysiology.  Med Clin North Am. 19911, 75:799-814. 10.1016\/s0025-7125(16)30412-6","journal-title":"Med Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0000000000000478","article-title":"Peptic ulcer disease","volume":"42","author":"Dunlap JJ","year":"2019","unstructured":"Dunlap JJ, Patterson S. Peptic ulcer disease. Gastroenterol Nurs. 2019, 42:451-4. 10.1097\/SGA.0000000000000478","journal-title":"Gastroenterol Nurs"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in treating patients with arthritis","volume":"15","author":"Crofford LJ","year":"2013","unstructured":"Crofford LJ. Use of NSAIDs in treating patients with arthritis.  Arthritis Res Ther. 2013, 15:","journal-title":"Arthritis Res Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados M","year":"2011","unstructured":"Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011, 70:249-51. 10.1136\/ard.2010.133488","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.07.016","article-title":"Design of balanced COX inhibitors based on anti-inflammatory and\/or COX-2 inhibitory ascidian metabolites","volume":"180","author":"Ju Z","year":"2019","unstructured":"Ju Z, Su M, Hong J, et al.. Design of balanced COX inhibitors based on anti-inflammatory and\/or COX-2 inhibitory ascidian metabolites. Eur J Med Chem. 2019, 180:86-98. 10.1016\/j.ejmech.2019.07.016","journal-title":"Eur J Med Chem"},{"key":"ref12","unstructured":"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease . (2023). Accessed. Jun 25, 2023: https:\/\/www.uptodate.com\/contents\/aspirin-for-the-secondary-prevention-of-atherosclerotic-cardiovascular-disease."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(99)00365-4","article-title":"Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)","volume":"13","author":"Rainsford KD","year":"1999","unstructured":"Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med. 1999, 13:27-35. 10.1016\/s0002-9343(99)00365-4","journal-title":"Am J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.907792","article-title":"Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies","volume":"13","author":"Salvo F","year":"2014","unstructured":"Salvo F, Antoniazzi S, Duong M, et al.. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2014, 13:573-85. 10.1517\/14740338.2014.907792","journal-title":"Expert Opin Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu S","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020, 180:114147. 10.1016\/j.bcp.2020.114147","journal-title":"Biochem Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(97)00203-9","article-title":"Mechanism of action of nonsteroidal anti-inflammatory drugs","volume":"30","author":"Vane JR","year":"1998","unstructured":"Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998, 30:2-8. 10.1016\/s0002-9343(97)00203-9","journal-title":"Am J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1965988","article-title":"Gastrointestinal and cardiovascular adverse events associated with NSAIDs","volume":"21","author":"Arnal MJ","year":"2022","unstructured":"Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022, 21:373-84. 10.1080\/14740338.2021.1965988","journal-title":"Expert Opin Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19201","article-title":"Potential strategies in the prevention of nonsteroidal anti-inflammatory drugs-associated adverse effects in the lower gastrointestinal tract","volume":"14","author":"Guo CG","year":"2020","unstructured":"Guo CG, Leung WK. Potential strategies in the prevention of nonsteroidal anti-inflammatory drugs-associated adverse effects in the lower gastrointestinal tract. Gut Liver. 2020, 14:179-89. 10.5009\/gnl19201","journal-title":"Gut Liver"},{"key":"ref19","article-title":"Physiology, aldosterone","author":"Scott JH","year":"2023","unstructured":"Scott JH, Menouar MA, Dunn RJ. Physiology, aldosterone. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000446268","article-title":"Potassium: from physiology to clinical implications","volume":"2","author":"Zacchia M","year":"2016","unstructured":"Zacchia M, Abategiovanni ML, Stratigis S, Capasso G. Potassium: from physiology to clinical implications. Kidney Dis (Basel). 2016, 2:72-9. 10.1159\/000446268","journal-title":"Kidney Dis (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182074c2f","article-title":"Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease","volume":"76","author":"Benarroch EE","year":"2011","unstructured":"Benarroch EE. Na+, K+-ATPase: functions in the nervous system and involvement in neurologic disease. Neurology. 2011, 76:287-93. 10.1212\/WNL.0b013e3182074c2f","journal-title":"Neurology"},{"key":"ref22","unstructured":"Potassium. Overview, uses, side effects, precautions, interactions, dosing and reviews. (2023). Accessed: Jun 27, 2023: https:\/\/www.webmd.com\/vitamins\/ai\/ingredientmono-851\/potassium."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174967","article-title":"Oral potassium supplementation for management of essential hypertension: a meta-analysis of randomized controlled trials","volume":"12","author":"Poorolajal J","year":"2017","unstructured":"Poorolajal J, Zeraati F, Soltanian AR, Sheikh V, Hooshmand E, Maleki A. Oral potassium supplementation for management of essential hypertension: a meta-analysis of randomized controlled trials. PLoS One. 2017, 12:e0174967. 10.1371\/journal.pone.0174967","journal-title":"PLoS One"},{"key":"ref24","article-title":"Potassium: Fact Sheet for Health Professionals","year":"2023","unstructured":"Potassium. Fact Sheet for Health Professionals. National Institutes of Health, 2023."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15414","article-title":"Potassium channelopathies and gastrointestinal ulceration","volume":"10","author":"Han J","year":"2016","unstructured":"Han J, Lee SH, Giebisch G, Wang T. Potassium channelopathies and gastrointestinal ulceration. Gut Liver. 2016, 10:881-9. 10.5009\/gnl15414","journal-title":"Gut Liver"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung M","year":"2013","unstructured":"McClung M, Harris ST, Miller PD, et al.. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013, 126:13-20. 10.1016\/j.amjmed.2012.06.023","journal-title":"Am J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub4","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan K","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016, 10:CD005088. 10.1002\/14651858.CD005088.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.12.006","article-title":"Alternative indications for bisphosphonate therapy","volume":"67","author":"Landesberg R","year":"2009","unstructured":"Landesberg R, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg. 2009, 67:27-34. 10.1016\/j.joms.2008.12.006","journal-title":"J Oral Maxillofac Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers MJ","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, 139:115493. 10.1016\/j.bone.2020.115493","journal-title":"Bone"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0085-6","article-title":"Bisphosphonate mechanism of action","volume":"5","author":"Reszka AA","year":"2003","unstructured":"Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003, 5:65-74. 10.1007\/s11926-003-0085-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref31","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer T","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al.. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000, 12:1-12.","journal-title":"Aging (Milano)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1027","article-title":"Benefits and risks of bisphosphonate therapy for osteoporosis","volume":"97","author":"Khosla S","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, et al.. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012, 97:2272-82. 10.1210\/jc.2012-1027","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L555","article-title":"Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate","volume":"43","author":"Blumentals WA","year":"2009","unstructured":"Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother. 2009, 43:577-85. 10.1345\/aph.1L555","journal-title":"Ann Pharmacother"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.19-00125","article-title":"Basic studies on the mechanism, prevention, and treatment of osteonecrosis of the Jaw induced by bisphosphonates (Article in Japanese)","volume":"140","author":"Endo Y","year":"2020","unstructured":"Endo Y, Funayama H, Yamaguchi K, et al..  Basic studies on the mechanism, prevention, and treatment of osteonecrosis of the Jaw induced by bisphosphonates (Article in Japanese). Yakugaku Zasshi. 2020, 140:63-79. 10.1248\/yakushi.19-00125","journal-title":"Yakugaku Zasshi"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2576-2","article-title":"Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis","volume":"25","author":"Tadrous M","year":"2014","unstructured":"Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, L\u00e9vesque LE, Cadarette SM. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int. 2014, 25:1225-35. 10.1007\/s00198-013-2576-2","journal-title":"Osteoporos Int"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0871-8","article-title":"Comparative gastrointestinal safety of weekly oral bisphosphonates","volume":"20","author":"Cadarette SM","year":"2009","unstructured":"Cadarette SM, Katz JN, Brookhart MA, St\u00fcrmer T, Stedman MR, Levin R, Solomon DH. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. 2009, 20:1735-47. 10.1007\/s00198-009-0871-8","journal-title":"Osteoporos Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2647-z","article-title":"Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study","volume":"25","author":"Peng YL","year":"2014","unstructured":"Peng YL, Hu HY, Luo JC, Hou MC, Lin HC, Lee FY. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporos Int. 2014, 25:1617-23. 10.1007\/s00198-014-2647-z","journal-title":"Osteoporos Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2014.05.002","article-title":"Alendronate induces gastric damage by reducing nitric oxide synthase expression and NO\/cGMP\/K(ATP) signaling pathway","volume":"40","author":"Silva RO","year":"2014","unstructured":"Silva RO, Lucetti LT, Wong DV, et al.. Alendronate induces gastric damage by reducing nitric oxide synthase expression and NO\/cGMP\/K(ATP) signaling pathway. Nitric Oxide. 2014, 40:22-30. 10.1016\/j.niox.2014.05.002","journal-title":"Nitric Oxide"},{"key":"ref39","article-title":"Antral ulcers induced by alendronate, a nitrogen-containing biphophonate, in rat stomachs - prophylactic effect of rebamipide","volume":"60","author":"Ohashi Y","year":"2009","unstructured":"Ohashi Y, Aihara E, Takasuka H, Takahashi K, Takeuchi K. Antral ulcers induced by alendronate, a nitrogen-containing biphophonate, in rat stomachs - prophylactic effect of rebamipide. J Physiol Pharmacol. 2009, 60:85-93.","journal-title":"J Physiol Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2278-2","article-title":"Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy","volume":"44","author":"Miyake K","year":"2009","unstructured":"Miyake K, Kusunoki M, Shinji Y, et al.. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009, 44:113-20. 10.1007\/s00535-008-2278-2","journal-title":"J Gastroenterol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06315-z","article-title":"Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates-a real-world cohort study","volume":"33","author":"Starup-Linde J","year":"2022","unstructured":"Starup-Linde J, Langdahl B, Vestergaard P, Harsl\u00f8f T. Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates-a real-world cohort study. Osteoporos Int. 2022, 33:1323-34. 10.1007\/s00198-022-06315-z","journal-title":"Osteoporos Int"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2174\/138161211796196927","article-title":"Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate - prophylactic effects of rebamipide","volume":"17","author":"Takeuchi K","year":"2011","unstructured":"Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing impairment actions of alendronate, a nitrogen-containing bisphosphonate - prophylactic effects of rebamipide. Curr Pharm Des. 2011, 17:1602-11. 10.2174\/138161211796196927","journal-title":"Curr Pharm Des"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3890-7","article-title":"Protective effects of simvastatin against alendronate-induced gastric mucosal injury in rats","volume":"61","author":"Carvalho NS","year":"2016","unstructured":"Carvalho NS, Silva MM, Silva RO, et al.. Protective effects of simvastatin against alendronate-induced gastric mucosal injury in rats\r\n. Dig Dis Sci. 2016, 61:400-9. 10.1007\/s10620-015-3890-7","journal-title":"Dig Dis Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra I","year":"2001","unstructured":"Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001, 65:232-60 ; second page, table of contents. 10.1128\/MMBR.65.2.232-260.2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref45","unstructured":"Doxycycline. MedlinePlus drug information . (2023). Accessed: Jun 27, 2023: https:\/\/medlineplus.gov\/druginfo\/meds\/a682063.html."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx420","article-title":"Doxycycline in the management of sexually transmitted infections","volume":"73","author":"Peyriere H","year":"2018","unstructured":"Peyriere H, Makinson A, Marchandin H, Reynes J. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother. 2018, 73:553-63. 10.1093\/jac\/dkx420","journal-title":"J Antimicrob Chemother"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1987.tb04037.x","article-title":"Increased frequency of doxycycline side effects","volume":"7","author":"Bryant SG","year":"1987","unstructured":"Bryant SG, Fisher S, Kluge RM. Increased frequency of doxycycline side effects. Pharmacotherapy. 1987, 7:125-9. 10.1002\/j.1875-9114.1987.tb04037.x","journal-title":"Pharmacotherapy"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.02.011","article-title":"Doxycycline-induced gastrointestinal injury","volume":"66","author":"Affolter K","year":"2017","unstructured":"Affolter K, Samowitz W, Boynton K, Kelly ED. Doxycycline-induced gastrointestinal injury. Hum Pathol. 2017, 66:212-5. 10.1016\/j.humpath.2017.02.011","journal-title":"Hum Pathol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4021\/gr498w","article-title":"Simultaneous esophageal and gastric ulceration due to doxycycline ingestion: case report and review of the literature","volume":"5","author":"Leber A","year":"2012","unstructured":"Leber A, Stal J. Simultaneous esophageal and gastric ulceration due to doxycycline ingestion: case report and review of the literature. Gastroenterology Res. 2012, 5:236-8. 10.4021\/gr498w","journal-title":"Gastroenterology Res"},{"key":"ref50","doi-asserted-by":"crossref","DOI":"10.1093\/milmed\/165.4.316","article-title":"Doxycycline-induced esophageal ulceration in the U.S. Military service","volume":"165","author":"Morris TJ","year":"2000","unstructured":"Morris TJ, Davis TP. Doxycycline-induced esophageal ulceration in the U.S. Military service. Mil Med. 2000, 165:316-9.","journal-title":"Mil Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.16677","article-title":"Long-term gastrointestinal adverse effects of doxycycline","volume":"17","author":"Eljaaly K","year":"2023","unstructured":"Eljaaly K, Alghamdi H, Almehmadi H, Aljawi F, Hassan A, Thabit AK. Long-term gastrointestinal adverse effects of doxycycline. J Infect Dev Ctries. 2023, 17:281-5. 10.3855\/jidc.16677","journal-title":"J Infect Dev Ctries"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.5.527","article-title":"Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration","volume":"28","author":"Armstrong CP","year":"1987","unstructured":"Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987, 28:527-32. 10.1136\/gut.28.5.527","journal-title":"Gut"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.124","article-title":"Effect of potassium chloride supplements on upper gastrointestinal mucosa","volume":"35","author":"McMahon FG","year":"1984","unstructured":"McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. Clin Pharmacol Ther. 1984, 35:852-5. 10.1038\/clpt.1984.124","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/213349-non-steroidal-anti-inflammatory-drug-nsaid--potassium-supplement--bisphosphonate--and-doxycycline-mediated-peptic-ulcer-effects-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:15:57Z","timestamp":1707509757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/213349-non-steroidal-anti-inflammatory-drug-nsaid--potassium-supplement--bisphosphonate--and-doxycycline-mediated-peptic-ulcer-effects-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.51894","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}